Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 5,860,000 shares, a growth of 19.3% from the October 15th total of 4,910,000 shares. Based on an average daily trading volume, of 504,200 shares, the short-interest ratio is presently 11.6 days. Currently, 13.3% of the shares of the stock are sold short.

Pyxis Oncology Stock Down 2.1 %

Shares of Pyxis Oncology stock traded down $0.09 on Friday, hitting $4.19. The stock had a trading volume of 793,622 shares, compared to its average volume of 750,478. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85. The company’s 50 day moving average price is $3.69 and its 200 day moving average price is $3.65.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. Equities research analysts expect that Pyxis Oncology will post -1.03 earnings per share for the current year.

Analysts Set New Price Targets

PYXS has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, August 16th. Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, September 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pyxis Oncology presently has an average rating of “Buy” and an average target price of $9.57.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently made changes to their positions in the company. StemPoint Capital LP acquired a new position in shares of Pyxis Oncology during the first quarter worth approximately $7,643,000. Ikarian Capital LLC bought a new stake in Pyxis Oncology during the 1st quarter worth approximately $7,082,000. Vanguard Group Inc. boosted its position in Pyxis Oncology by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after acquiring an additional 94,740 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after buying an additional 743,499 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after purchasing an additional 57,016 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.